The American Journal of Surgery
Volume 197, Issue 3 , Pages 308-312 , March 2009

The influence of 18flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma

  • Jason W. Smith, M.D.

      Affiliations

    • Department of Surgery, Loyola University Medical Center, Maywood, IL, USA
    • ,
  • Jonathan Moreira, B.S.

      Affiliations

    • Department of Surgery, Loyola University Medical Center, Maywood, IL, USA
    • ,
  • Gerard Abood, M.D.

      Affiliations

    • Department of Surgery, Loyola University Medical Center, Maywood, IL, USA
    • ,
  • Gerard V. Aranha, M.D., F.R.C.S.C., FACS

      Affiliations

    • Department of Surgery, Loyola University Medical Center, Maywood, IL, USA
    • ,
  • Suneel Nagda, M.D.

      Affiliations

    • Department of Radiation Oncology, Loyola University Medical Center, Maywood, IL, USA
    • ,
  • Robert H. Wagner, M.D.

      Affiliations

    • Department of Nuclear Medicine, Loyola University Medical Center, Maywood, IL, USA
    • ,
  • Margo Shoup, M.D., FACS

      Affiliations

    • Department of Surgery, Loyola University Medical Center, Maywood, IL, USA
    • Corresponding Author InformationCorresponding author. Tel.: +01-708-327-3430; fax: +01-708-327-3565

Received 4 August 2008 ,Revised 15 October 2008

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99:1384–1394
  3. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29
  4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  5. Sauvanet A, Mariette C, Thomas P, et al. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg. 2005;201:253–262
  6. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376–75
  7. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–2252
  8. Schmidt GP, Kramer H, Reiser MF, et al. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top Magn Reson Imaging. 2007;18:193–202
  9. Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus. 2006;19:433–442
  10. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507
  11. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–3210
  12. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428–432
  13. McDonough PB, Jones DR, Shen KR, et al. Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? (A prospective single center study). Am J Gastroenterol. 2008;103:570–574
  14. van Westreenen HL, Westerterp M, Sloof GW, et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg. 2007;94:1515–1520
  15. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–1459
  16. In:  Greene FL,  Fleming I,  Fritz A editor. AJCC cancer staging manual. 6th ed.. Lippincott-Raven; 2003;
  17. Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007;133:738–745
  18. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–4698
  19. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON Phase II trial. Lancet Oncol. 2007;8:797–805
  20. Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925–1932

PII: S0002-9610(08)00821-0

doi: 10.1016/j.amjsurg.2008.10.010

The American Journal of Surgery
Volume 197, Issue 3 , Pages 308-312 , March 2009

Article Tools

* Image Usage & Resolution